{"id":8264,"date":"2024-03-01T23:29:36","date_gmt":"2024-03-01T15:29:36","guid":{"rendered":"https:\/\/flcube.com\/?p=8264"},"modified":"2024-10-20T23:33:09","modified_gmt":"2024-10-20T15:33:09","slug":"cde-grants-priority-review-to-jiu-ans-adrenaline-and-anhearts-taletrectinib-two-others-earn-breakthrough-therapy-designation","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=8264","title":{"rendered":"CDE Grants Priority Review to Jiu An&#8217;s Adrenaline and AnHeart\u2019s Taletrectinib; Two Others Earn Breakthrough Therapy Designation"},"content":{"rendered":"\n<p>The Center for Drug Evaluation (CDE) has announced that Jiu An Pharmaceutical&#8217;s adrenaline and AnHeart Therapeutics&#8217; taletrectinib are set for priority review, while Biotheus Inc.&#8217;s PM8002 and Sichuan Kelun Pharmaceutical Co., Ltd. (SHE: 002422)&#8217;s SKB264 have been designated as breakthrough therapies (BTDs).<\/p>\n\n\n\n<p>Adrenaline is gaining priority status due to new pediatric specifications aimed at treating acute hypersensitivity reactions and asthma attacks, preventing and managing cardiac arrest and transient atrioventricular block with syncope, and increasing average arterial blood pressure in adult patients with septic shock-related hypotension.<\/p>\n\n\n\n<p>Taletrectinib, an ROS1\/NTRK inhibitor initially developed by Daiichi Sankyo (<a href=\"https:\/\/www.google.com\/finance\/quote\/4568:TYO\">TYO: 4568<\/a>), was acquired by AnHeart in December 2018 for global development. The drug received BTD status in Greater China in February 2022 and is intended for ROS1-positive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received ROS1-TKI treatment.<\/p>\n\n\n\n<p>PM8002 features humanized anti-PD-L1 single heavy-chain variable (VHH) domains fused with an anti-VEGF-A IgG1 antibody, designed for first-line treatment of inoperable locally advanced or recurrent metastatic triple-negative breast cancer in combination with chemotherapy. The drug was licensed to BioNTech for global development earlier this year.<\/p>\n\n\n\n<p>SKB264, a TROP2-targeted antibody-drug conjugate (ADC), received BTD status for treating non-resectable locally advanced, recurrent, or metastatic PD-L1 negative and triple-negative breast cancer without prior systematic treatment. This drug was part of a licensing agreement with Merck, Sharp &amp; Dohme (MSD) for territories outside Greater China in May 2022.- <a href=\"https:\/\/flcube.com\">Flcube.com<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Center for Drug Evaluation (CDE) has announced that Jiu An Pharmaceutical&#8217;s adrenaline and AnHeart&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,34,16,194,371,80,1185,978],"class_list":["post-8264","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-breakthrough-therapy","tag-cancer","tag-daiichi-sankyo","tag-kelun-pharmaceutical","tag-priority-reviews","tag-she-002422","tag-tyo-4568"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CDE Grants Priority Review to Jiu An&#039;s Adrenaline and AnHeart\u2019s Taletrectinib; Two Others Earn Breakthrough Therapy Designation - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The Center for Drug Evaluation (CDE) has announced that Jiu An Pharmaceutical&#039;s adrenaline and AnHeart Therapeutics&#039; taletrectinib are set for priority review, while Biotheus Inc.&#039;s PM8002 and Sichuan Kelun Pharmaceutical Co., Ltd. (SHE: 002422)&#039;s SKB264 have been designated as breakthrough therapies (BTDs).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=8264\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CDE Grants Priority Review to Jiu An&#039;s Adrenaline and AnHeart\u2019s Taletrectinib; Two Others Earn Breakthrough Therapy Designation\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=8264\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-01T15:29:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-20T15:33:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8264#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8264\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CDE Grants Priority Review to Jiu An&#8217;s Adrenaline and AnHeart\u2019s Taletrectinib; Two Others Earn Breakthrough Therapy Designation\",\"datePublished\":\"2024-03-01T15:29:36+00:00\",\"dateModified\":\"2024-10-20T15:33:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8264\"},\"wordCount\":258,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Breakthrough therapy\",\"Cancer\",\"Daiichi Sankyo\",\"Kelun Pharmaceutical\",\"Priority reviews\",\"SHE: 002422\",\"TYO: 4568\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=8264#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8264\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=8264\",\"name\":\"CDE Grants Priority Review to Jiu An's Adrenaline and AnHeart\u2019s Taletrectinib; Two Others Earn Breakthrough Therapy Designation - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-03-01T15:29:36+00:00\",\"dateModified\":\"2024-10-20T15:33:09+00:00\",\"description\":\"The Center for Drug Evaluation (CDE) has announced that Jiu An Pharmaceutical's adrenaline and AnHeart Therapeutics' taletrectinib are set for priority review, while Biotheus Inc.'s PM8002 and Sichuan Kelun Pharmaceutical Co., Ltd. (SHE: 002422)'s SKB264 have been designated as breakthrough therapies (BTDs).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8264#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=8264\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8264#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CDE Grants Priority Review to Jiu An&#8217;s Adrenaline and AnHeart\u2019s Taletrectinib; Two Others Earn Breakthrough Therapy Designation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CDE Grants Priority Review to Jiu An's Adrenaline and AnHeart\u2019s Taletrectinib; Two Others Earn Breakthrough Therapy Designation - Insight, China&#039;s Pharmaceutical Industry","description":"The Center for Drug Evaluation (CDE) has announced that Jiu An Pharmaceutical's adrenaline and AnHeart Therapeutics' taletrectinib are set for priority review, while Biotheus Inc.'s PM8002 and Sichuan Kelun Pharmaceutical Co., Ltd. (SHE: 002422)'s SKB264 have been designated as breakthrough therapies (BTDs).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=8264","og_locale":"en_US","og_type":"article","og_title":"CDE Grants Priority Review to Jiu An's Adrenaline and AnHeart\u2019s Taletrectinib; Two Others Earn Breakthrough Therapy Designation","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=8264","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-03-01T15:29:36+00:00","article_modified_time":"2024-10-20T15:33:09+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=8264#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=8264"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CDE Grants Priority Review to Jiu An&#8217;s Adrenaline and AnHeart\u2019s Taletrectinib; Two Others Earn Breakthrough Therapy Designation","datePublished":"2024-03-01T15:29:36+00:00","dateModified":"2024-10-20T15:33:09+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=8264"},"wordCount":258,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Breakthrough therapy","Cancer","Daiichi Sankyo","Kelun Pharmaceutical","Priority reviews","SHE: 002422","TYO: 4568"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=8264#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=8264","url":"https:\/\/flcube.com\/?p=8264","name":"CDE Grants Priority Review to Jiu An's Adrenaline and AnHeart\u2019s Taletrectinib; Two Others Earn Breakthrough Therapy Designation - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-03-01T15:29:36+00:00","dateModified":"2024-10-20T15:33:09+00:00","description":"The Center for Drug Evaluation (CDE) has announced that Jiu An Pharmaceutical's adrenaline and AnHeart Therapeutics' taletrectinib are set for priority review, while Biotheus Inc.'s PM8002 and Sichuan Kelun Pharmaceutical Co., Ltd. (SHE: 002422)'s SKB264 have been designated as breakthrough therapies (BTDs).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=8264#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=8264"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=8264#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CDE Grants Priority Review to Jiu An&#8217;s Adrenaline and AnHeart\u2019s Taletrectinib; Two Others Earn Breakthrough Therapy Designation"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/8264","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=8264"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/8264\/revisions"}],"predecessor-version":[{"id":8265,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/8264\/revisions\/8265"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=8264"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=8264"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=8264"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}